---
title: "Maxim Group Keeps Their Buy Rating on Nuvectis Pharma (NVCT)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293777709.md"
description: "Maxim Group analyst Naz Rahman reiterated a Buy rating on Nuvectis Pharma (NVCT) with a $30.00 price target. This follows H.C. Wainwright also maintaining a Buy rating with a higher $39.00 target. Rahman, who covers the healthcare sector, has a historical success rate of 36.93% on recommended stocks."
datetime: "2026-07-24T15:36:52.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293777709.md)
  - [en](https://longbridge.com/en/news/293777709.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293777709.md)
---

# Maxim Group Keeps Their Buy Rating on Nuvectis Pharma (NVCT)

In a report released yesterday, Naz Rahman from Maxim Group reiterated a Buy rating on Nuvectis Pharma, with a price target of $30.00.

### Claim 55% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

Rahman covers the Healthcare sector, focusing on stocks such as Nuvectis Pharma, Vertex Pharmaceuticals, and Vivani Medical. According to TipRanks, Rahman has an average return of \-7.5% and a 36.93% success rate on recommended stocks.

In a report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $39.00 price target.

### Related Stocks

- [NVCT.US](https://longbridge.com/en/quote/NVCT.US.md)
- [VRTX.US](https://longbridge.com/en/quote/VRTX.US.md)
- [VANI.US](https://longbridge.com/en/quote/VANI.US.md)

## Related News & Research

- [Nuvectis Pharma: Buy Rating Reiterated as Late-Stage Pipeline Expands and $39 Price Target Remains Unchanged](https://longbridge.com/en/news/294852722.md)
- [Nuvectis Pharma (NASDAQ:NVCT) Shares Gap Down  After Earnings Miss](https://longbridge.com/en/news/294839631.md)
- [Amadeus IT Group: Operational Resilience and Margin Outperformance Support Unchanged $60 Price Target and Buy Rating](https://longbridge.com/en/news/294469810.md)
- [Healthcare of Ontario Pension Plan Trust Fund Increases Position in Webull Corporation $BULL](https://longbridge.com/en/news/294484857.md)
- [Goldman Sachs Reaffirms Their Buy Rating on Haleon PLC (HLN)](https://longbridge.com/en/news/294464159.md)